Results 31 to 40 of about 2,212 (184)

A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of Interleukin-1 receptor antagonist (DIRA)

open access: yesPediatric Rheumatology Online Journal, 2020
Background Deficiency of the natural antagonist of interleukin-1 was first described in 2009 and so far 20 patients has been reported. In Brazil just two cases have been reported both carrying the same homozygous 15 bp deletion.
Leonardo Oliveira Mendonça   +9 more
doaj   +1 more source

Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis [PDF]

open access: yesThe Journal of Clinical Pharmacology, 2014
Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by arthritis in children
Julie Autmizguine   +3 more
openaire   +2 more sources

Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension. [PDF]

open access: yes
BACKGROUND: Rilonacept inhibits the interleukin-1 pathway, and extended treatment in patients with recurrent pericarditis (RP) reduced recurrence risk by 98% in the phase 3 trial, RHAPSODY long-term extension (LTE).
Klutstein, Marc   +16 more
core   +3 more sources

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis [PDF]

open access: yes, 2014
OBJECTIVE: To assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial. METHODS: An initial 4-week double-blind placebo phase was incorporated into a 24-week randomized multicenter ...
Spalding, S. J.   +10 more
core   +1 more source

Synovial Tissue‐Guided Interleukin‐17A Inhibition for Refractory Arthritis in a Patient With Systemic Juvenile Idiopathic Arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The objective of this study was to characterize the clinical, immunologic, and synovial tissue features of a patient with a systemic juvenile idiopathic arthritis (sJIA) who carries a novel heterozygous STAT5B loss‐of‐function variant (p.Gln139Ter) and whose arthritis responded markedly to interleukin‐17A (IL‐17A) inhibition.
Indira Sriram   +14 more
wiley   +1 more source

Successful Treatment of Recurrent Pericarditis With Rilonacept in Acute Promyelocytic Leukemia

open access: yesJACC: Case Reports, 2023
A 40-year-old woman presented with recurrent pericarditis and pericardial effusion while receiving treatment with all-trans retinoic acid and arsenic trioxide for recently diagnosed acute promyelocytic leukemia. She was successfully treated with the interleukin-1 inhibitor rilonacept after experiencing multiple recurrences with triple therapy with ...
Mustafa Atar   +9 more
openaire   +2 more sources

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

A Mechanism‐Based Framework for Anti‐Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell‐Based Interventions

open access: yesAging Cell, Volume 25, Issue 9, September 2026.
The aging of the human body is a complex process driven by multiple contributing factors. Based on their underlying mechanisms, current anti‐aging interventions can be classified into six primary categories. This paper summarizes the most promising anti‐aging strategies within each class. ABSTRACT The global prevalence of aging and age‐related diseases
Feifei Li   +4 more
wiley   +1 more source

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator [PDF]

open access: yes, 2013
Introduction In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for gout flare prevention during initiation of urate-lowering therapy.
Robert A Terkeltaub   +15 more
core   +1 more source

Metabolic Regulation of Macrophages in Health and Disease

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy